KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Change in Accured Expenses (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Change in Accured Expenses for 13 consecutive years, with $806000.0 as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 3930.0% to $806000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.1 million through Dec 2025, up 22.24% year-over-year, with the annual reading at -$2.1 million for FY2025, 22.24% up from the prior year.
  • Change in Accured Expenses hit $806000.0 in Q4 2025 for Arbutus Biopharma, up from -$2.7 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $6.2 million in Q2 2023 to a low of -$6.4 million in Q1 2023.
  • Historically, Change in Accured Expenses has averaged $93550.0 across 5 years, with a median of -$91000.0 in 2024.
  • Biggest five-year swings in Change in Accured Expenses: surged 13490.0% in 2021 and later tumbled 8401.33% in 2023.
  • Year by year, Change in Accured Expenses stood at $2.2 million in 2021, then skyrocketed by 155.2% to $5.5 million in 2022, then plummeted by 102.82% to -$155000.0 in 2023, then surged by 112.9% to $20000.0 in 2024, then surged by 3930.0% to $806000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for ABUS at $806000.0 in Q4 2025, -$2.7 million in Q3 2025, and -$121000.0 in Q2 2025.